Tuesday was a good day for AstraZeneca's oncology pipeline. The company announced two major developments: positive Phase 3 trial results for a lung cancer combination therapy and a new European Union approval for its breast cancer drug Enhertu. Let's break down what happened and why it matters.
AstraZeneca's Double Win: Lung Cancer Data and EU Approval for Enhertu
MarketDash
AstraZeneca reports positive Phase 3 lung cancer trial results and secures EU approval for its Enhertu breast cancer combination, marking a strong day for its oncology pipeline.
Get Astrazeneca Alerts
Weekly insights + SMS alerts
Lung Cancer Combo Hits the Mark
First up, the SANOVO Phase 3 trial. This study tested Tagrisso combined with Orpathys in patients with untreated, EGFR-mutated, locally advanced or metastatic non-small cell lung cancer (NSCLC) that also shows MET overexpression. The results were clear: the combination significantly improved progression-free survival compared to Tagrisso alone, and this benefit was seen in both the high MET group and the overall intention-to-treat population.
The trial also showed encouraging trends in overall survival, which was a secondary endpoint. That's a good sign, though we'll need to wait for more mature data to see if it's a home run.
Orpathys is a joint effort with HUTCHMED Ltd. (HCM), but AstraZeneca holds the sole commercialization rights. This isn't the first time the combo has shown promise. Earlier studies, including SACHI and SAFFRON, already demonstrated clinical benefits, and the drug is already approved in China. So this new data just adds to the growing evidence.
Enhertu Gets EU Green Light
On the breast cancer front, the European Commission has approved Enhertu (from AstraZeneca and Daiichi Sankyo) in combination with pertuzumab as a first-line treatment for adults with unresectable or metastatic HER2-positive breast cancer. This follows a positive recommendation from the European Medicines Agency's medicinal committee.
The approval is based on the DESTINY-Breast09 trial, which showed that the Enhertu combo cut the risk of disease progression or death by 44% compared to standard THP therapy. Median progression-free survival was 40.7 months versus 26.9 months for THP. That's a substantial improvement, and it's why regulators were quick to sign off.
And there's more in the pipeline: European regulators are also reviewing Enhertu for residual invasive HER2-positive breast cancer, based on data from the DESTINY-Breast05 study. So this drug could be expanding its reach even further.
Despite all this good news, AstraZeneca shares were down 0.81% at $160.81 in premarket trading on Tuesday. Sometimes the market just doesn't react the way you'd expect, but long-term investors might see this as a buying opportunity.
Overall, AstraZeneca is clearly doubling down on oncology, and these latest wins could solidify its position in the cancer treatment space.
More News
Stock Market Today: S&P 500, Dow Futures Slide as Trump Declares Iran 'Totally Defeated', Brent Tops $92 — CBRS, PXS, PANW, DELL in Focus
Trump's 'Historic' Venezuela Oil Deal: 100-Year Rights, 65 Billion Barrels, and a 35% Equity Stake for the U.S.
Broadcom Stock Dips Ahead of Earnings as VMware AI Push Takes Center Stage
Peter Schiff Warns of 8% Treasury Yields and 10% Mortgage Rates as Bond Market Enters 'Bear Market'
Treasury Secretary Warns Iran's Economy Could Collapse 'Within Weeks or Months' as Sanctions Bite
Trump's Venezuela Oil Deal: A Refining Reality Check
Analyst Slams Trump’s Energy Promises, Strait of Hormuz Claims: ‘A Painful New Record…’
Trump Jr.-Linked Firm Leads $1B Polymarket Round, Valuing Platform at $21B
Get Astrazeneca Alerts
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
Featured Articles
View all newsStock Market Today: S&P 500, Dow Futures Slide as Trump Declares Iran 'Totally Defeated', Brent Tops $92 — CBRS, PXS, PANW, DELL in Focus
By MarketDash
September 1, 2026
Trump's 'Historic' Venezuela Oil Deal: 100-Year Rights, 65 Billion Barrels, and a 35% Equity Stake for the U.S.
By MarketDash
September 1, 2026
Broadcom Stock Dips Ahead of Earnings as VMware AI Push Takes Center Stage
By MarketDash
September 1, 2026
Peter Schiff Warns of 8% Treasury Yields and 10% Mortgage Rates as Bond Market Enters 'Bear Market'
By MarketDash
September 1, 2026
Treasury Secretary Warns Iran's Economy Could Collapse 'Within Weeks or Months' as Sanctions Bite
By MarketDash
September 1, 2026
Trump's Venezuela Oil Deal: A Refining Reality Check
By MarketDash
September 1, 2026
Analyst Slams Trump’s Energy Promises, Strait of Hormuz Claims: ‘A Painful New Record…’
By MarketDash
September 1, 2026
Trump Jr.-Linked Firm Leads $1B Polymarket Round, Valuing Platform at $21B
By MarketDash
September 1, 2026